ClinicalTrials.gg
Sign In
Not yet recruitingNCT07880834EPI-FLU-EAUUpdated Oct 19, 2026

Wastewater Epidemiology to Document the Circulation of Influenza Viruses

An observational study in FLU, sponsored by Central Hospital, Nancy, France. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Central Hospital, Nancy, France · Observational

Updated Oct 19, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
300
Sex
All
01

Study summary

Primary objective:

To evaluate the wastewater surveillance strategy for anticipating the circulation of influenza virus strains in the general population and among hospitalized patients.

Secondary objective:

To compare the sequences of influenza viruses isolated from wastewater (reflecting viruses circulating in the general population) with those of strains isolated from patients hospitalized .

To identify genetic mutations corresponding to viral variants that may exhibit increased virulence.

02

Conditions studied

  • FLU

Keywords

  • FLU
  • Wastewater based epidemiology
03

In context

Lead sponsor

Central Hospital, Nancy, France is the lead sponsor of 796 studies on the registry; 187 are open to participants now.

Browse Central Hospital, Nancy, France studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient hospitalized in the Nancy Hospital with a molecular diagnosis of FLU

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • infection by FLu documented by RTPCR

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patient infected by FLU

    Patient infected by FLU

06

What researchers measure

Primary outcomes

  1. Flu sequencing

    Sequencing of the virus isolated from patient (nasal swab)

    Time frame: at the inclusion

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2026, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2026
First posted
Oct 19, 2026
StartEst.
Dec 2026
Primary completionEst.
Dec 2026
CompletionEst.
Apr 2029
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07880834
Lead sponsor
Central Hospital, Nancy, France
Responsible party
HARTARD Cédric (Dr, Central Hospital, Nancy, France) — Principal investigator
First posted
Oct 19, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Apr 2029 (estimated)
Last update
Oct 19, 2026

Study contacts

Cédric Hartard, DR
Contact
c.hartard@chru-nancy.fr
0383153046

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Central Hospital, Nancy, France →

Start the discussion